Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2026-03-06 Share Issue/Capital Cha…
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding a decision to issue new shares through a third-party allocation (유상증자결정). This type of filing is a standard regulatory announcement for capital changes in the Korean market, which falls under the 'Share Issue/Capital Change' category.
2026-03-06 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kolon TissueGene, Inc. It details the meeting date, location, agenda items (including financial statement approval, director/auditor appointments, and remuneration limits), and voting procedures. It also includes supplementary information such as board activity reports and transaction details with related parties, which are standard components of proxy materials provided to shareholders to facilitate informed voting. This fits the definition of a Proxy Solicitation & Information Statement.
2026-03-06 Korean
전환청구권행사
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from Kolon TissueGene regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. It details the number of shares issued, the conversion price, and the remaining balance of convertible bonds. This type of filing relates to capital changes resulting from the conversion of debt into equity, which falls under the 'Share Issue/Capital Change' category.
2026-03-04 Korean
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Kolon TissueGene regarding a legal proceeding (a lawsuit for damages). It specifically details a 'Correction Report' (정정신고) for a previously filed lawsuit disclosure, updating the case number and the court of jurisdiction. Since the document pertains to ongoing legal proceedings and litigation updates, it falls under the 'Legal Proceedings Report' category.
2026-02-26 Korean
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Kolon TissueGene regarding a 'Lawsuit/Legal Proceeding' (소송등의제기ㆍ신청). It details a correction (정정신고) to a previously filed lawsuit disclosure, specifically updating the number of plaintiffs and the total claim amount. Since this document reports on significant legal proceedings and litigation updates, it falls under the 'Legal Proceedings Report' category.
2026-02-20 Korean
파생상품거래손실발생
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Kolon TissueGene regarding a 'Loss from Derivatives Transaction' (파생상품거래손실발생). It details the accounting loss related to convertible bonds, specifically noting that it is a non-cash accounting loss. This type of disclosure is a standard regulatory requirement for material financial events in the Korean market (KRX). Since it does not fit into specific categories like dividends, share buybacks, or management changes, and is a formal regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2026-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.